ArticleCancer medicine2019
Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States.Prostate cancer and prostatic diseases · 2026Article
- Racial Differences in Secondary Treatment Pathways and Survival in Localized Prostate Cancer.JAMA network open · 2026Article
- Sociodemographic disparities in prostate cancer imaging.Abdominal radiology (New York) · 2026Review
- Comparing Black and White Patients in Treatment of Advanced Prostate Cancer and Survival in an Equal Access Health System.Journal of racial and ethnic health disparities · 2025Article
- Understanding Racial Disparities in Prostate Cancer: A Multifaceted Approach.Cancer medicine · 2025Review
- Racial Disparities in the Prescribing of Guideline-Recommended Medications for Metastatic Prostate Cancer: A Retrospective Cohort Study.Prostate cancer · 2025Article
- Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- A scoping review of racial, ethnic, socioeconomic, and geographic disparities in the outcomes of older adults with cancer.Journal of the American Geriatrics Society · 2024Article
- Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease.Cancer medicine · 2024Article
- Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer.Urology practice · 2024Article
- Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Current Status and Future Direction to Address Disparities in Diversity, Equity, and Inclusion in Prostate Cancer Care.Current oncology reports · 2023Review
- Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population.British journal of cancer · 2023Article
- Influencing factors for mortality in prostate cancer patients with T1 and T2 stage: a retrospective cohort study.Translational andrology and urology · 2023Article
- Review
- Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer.Advances in therapy · 2022Article
- Stigma May Exacerbate Disproportionately Low Guideline-Concordant Treatment Rates for Patients With Advanced-Stage Lung Cancer in the United States.JTO clinical and research reports · 2022Article
- Reporting of Racial Health Disparities Research: Are We Making Progress?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
purposeApproximately 5% of men were initially diagnosed with (also referred to as de novo) advanced stage prostate cancer and experience far poorer survival compared to men diagnosed with local or regionally advanced disease. Given the number of new therapies targeting metastatic and castrate-resistant disease, we sought to describe recent treatment patterns by race for de novo AJCC stage IV prostate cancer.
methodsWe used Surveillance, Epidemiology, and End Results (SEER) data linked to Medicare files to identify men aged 66 and older diagnosed in 2004-2014 with advanced prostate cancer, and examined patterns of treatment among all patients and stratified by race/ethnicity.
resultsThere were 8828 eligible patients identified, and non-Hispanic black (NHB) patients were more likely to go without treatment (P < 0.001) compared to non-Hispanic white (NHW) patients, even after accounting for early mortality and TNM stage. The frequency of nearly all forms of treatment was lower among NHB with the exception of orchiectomy, which was significantly higher (10.1% vs 6.1%, P < 0.001), and the use of the progesterone Megace among Medicare Part D enrollees (24.6% vs 15.0%, P < 0.001).
conclusionsResults from this study of elderly Medicare patients presenting with advanced stage prostate cancer suggest that NHB men are less likely to pursue aggressive treatment options. With the reduction in screening for prostate cancer, presumably tied to USPSTF recommendations, and the increasing incidence of men diagnosed with de novo metastatic disease, understanding drivers of treatment-related decisions are critical in reducing racial disparities in advanced prostate cancer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.